New Copper-Peptide-Hyaluronan Conjugates Boost Bone and Blood Vessel Growth

The tripeptide Glycyl-l-histidyl-l-lysine (GHK), particularly its copper complex GHK-Cu, is renowned for its potent wound healing, anti-inflammatory, and antioxidant properties. Hyaluronan (HA), a key component of the extracellular matrix, is also critical for tissue repair and regeneration. While both are individually beneficial, there's a significant knowledge gap regarding the potential for synergistic osteogenic (bone-forming) and angiogenic (blood vessel-forming) effects when GHK-Cu is conjugated with Hyaluronan.

The study revealed that the GHK-Cu-HA conjugate exhibited significantly enhanced biological activities compared to its individual components. In antioxidant assays, the conjugate demonstrated a 2.5-fold higher radical scavenging activity than GHK-Cu alone, indicating superior protection against oxidative stress. For osteogenic potential, GHK-Cu-HA treatment led to a 43% increase in alkaline phosphatase (ALP) activity and a 35% increase in calcium deposition in osteoblasts, both critical markers for bone formation. Angiogenesis was also profoundly impacted, with endothelial cells treated with the conjugate showing a 60% enhancement in tube formation and a 2.1-fold upregulation of VEGF (Vascular Endothelial Growth Factor, a protein that promotes new blood vessel growth) expression. The most striking finding was the profound synergistic effect: the GHK-Cu-HA conjugate significantly outperformed individual GHK-Cu or Hyaluronan treatments in promoting both osteogenesis and angiogenesis, with statistical significance reaching p<0.001 for several key markers.